Appendix B Statin Therapy Based on ACC/AHA Guidelines High-Intensity Moderate-Intensity Low-Intensity by ~50% by ~30-50% by <30% LDL LDL LDL Atorvastatin 40-80mg Atorvastatin 10-20mg Simvastatin 5-10mg Rosuvastatin 20-40mg Rosuvastatin 5-10mg Pravastatin 10-20mg Simvastatin 20-40mg Lovastatin 20mg Pravastatin 40-80mg Fluvastatin 20-40mg Lovastatin 40mg Pitavastatin 1mg Fluvastatin XL 80mg Fluvastatin 40mg BID Pitavastatin 2-4mg Treatment Recommendations Based on AACE Guidelines Statins first-line therapy If lipid levels are not at goal, intensify statin and: + Ezetimibe + colesevelam + niacin LDL-C: TG: + + fatty acids + fibrates + niacin Non-HDL-C, LDL-P: + Ezetimibe + colesevelam + niacin ApoB, By singing this document, the named physicians agree that the named pharmacist may enter into Collaborative Practice with them for the management of hyperlipidemia in residents at Hickory Grove and Maple Grove receiving antihyperlipidemia therapy in accordance with policies and procedures outlined in the above document and mutually agreed upon, as well as the Illinois Pharmacy Practice Act 225 ILCS 85/3 (aa). Clinical Pharmacists:
Appendix B Statin Therapy Based on ACC/AHA Guidelines High-Intensity Moderate-Intensity Low-Intensity LDL by ~50% LDL by ~30-50% LDL by <30% Atorvastatin 40-80mg Rosuvastatin 20-40mg Atorvastatin 10-20mg Rosuvastatin 5-10mg Simvastatin 20-40mg Pravastatin 40-80mg Lovastatin 40mg Fluvastatin XL 80mg Fluvastatin 40mg BID Pitavastatin 2-4mg Simvastatin 5-10mg Pravastatin 10-20mg Lovastatin 20mg Fluvastatin 20-40mg Pitavastatin 1mg Treatment Recommendations Based on AACE Guidelines Statins first-line therapy If lipid levels are not at goal, intensify statin and: LDL-C: + Ezetimibe + colesevelam + niacin Non-HDL-C, TG: + + fatty acids + fibrates + niacin ApoB, LDL-P: + Ezetimibe + colesevelam + niacin By singing this document, the named physicians agree that the named pharmacist may enter into Collaborative Practice with them for the management of hyperlipidemia in residents at Hickory Grove and Maple Grove receiving antihyperlipidemia therapy in accordance with policies and procedures outlined in the above document and mutually agreed upon, as well as the Illinois Pharmacy Practice Act 225 ILCS 85/3 (aa). Clinical Pharmacists:
CPFGrantDoc_88610.docx